跳至主要内容
临床试验/ISRCTN93591221
ISRCTN93591221已完成未知

Prospective early feasibility study utilizing a novel mapping catheter for mapping in the atria and ventricles

Biosense Webster, Inc.0 个研究点目标入组 30 人开始时间: 2018年8月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Diagnosed with and is a candidate for clinically-indicated catheter ablation procedure for the management of:
  • 1.1. Ischemic ventricular tachycardia
  • 1.2. Atrial tachycardia/atypical atrial flutter/paroxysmal atrial fibrillation following a pulmonary vein isolation ablation or mitral valve repair procedure
  • 1.3. Persistent atrial fibrillation
  • 2. Aged 18 years or older
  • 3. Able to provide informed consent
  • 4. Able and willing to comply with all pre-, post-, and follow-up testing and requirements

排除标准

  • 1. History of continuous atrial fibrillation (AF) sustained longer than 12 months
  • 2. History of AF <7 days and no previous AF ablation procedure
  • 3. Previously diagnosed with long-standing persistent atrial fibrillation
  • 4. Previously diagnosed with idiopathic PVC/VT
  • 5. Study arrhythmia secondary to reversible cause
  • 6. Atrial arrhythmias: patients with a left atrial size >55 mm
  • 7. LVEF = 25% for VT patients
  • 8. LVEF = 40% for AF patients
  • 9. Documented thrombus in the chamber to be mapped by the study catheter on imaging
  • 10. Contraindication to anticoagulation (i.e. heparin, warfarin, dabigatran)
  • 11. History of blood clotting or bleeding abnormalities (e.g. hypercoagulable state)
  • 12. Myocardial infarction within the past 2 months (60 days)
  • 13. Documented thromboembolic event (including TIA) within the past 12 months (365 days)
  • 14. Uncontrolled heart failure or NYHA function class III or IV
  • 15. Implanted with a pacemaker or intracardiac cardiac defibrillator within the past 3 months (90 days)
  • 16. Implanted with a prosthetic valve
  • 17. Active systemic infection
  • 18. Diagnosed atrial or ventricular myxoma
  • 19. Implanted with an interatrial baffle or patch
  • 20. Atrial septal closure within the past 6 weeks (42 days)
  • 21. Presence of a condition that precludes vascular access
  • 22. Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation
  • 23. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)
  • 24. Enrollment in an investigational study evaluating another device or drug

研究者

相似试验

Study utilizing a novel mapping catheter in heart... | 临床试验